Inhibiting the TREM2 gene can trigger the anti-tumor activity of GBM myeloid cells, increase interferon-γ induced immune activation, and promote pro-inflammatory phenotypes, ultimately inhibiting tumor growth and prolonging survival (22). The gene discussed is TREM2; the disease is glioblastoma.